Literature DB >> 28266515

Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment.

Anna M Czarnecka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28266515     DOI： 10.1038/nrurol.2017.36

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

2.  Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.

Authors:  A M Molina; X Lin; B Korytowsky; E Matczak; M J Lechuga; R Wiltshire; R J Motzer
Journal:  Eur J Cancer       Date:  2013-09-16       Impact factor: 9.162

3.  Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention.

Authors:  Xue-Song Li; Lin Yao; Kan Gong; Wei Yu; Qun He; Li-Qun Zhou; Zhi-Song He
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-22       Impact factor: 4.553

4.  A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.

Authors:  Moshe C Ornstein; Laura S Wood; Paul Elson; Kimberly D Allman; Jennifer Beach; Allison Martin; Beth R Zanick; Petros Grivas; Tim Gilligan; Jorge A Garcia; Brian I Rini
Journal:  J Clin Oncol       Date:  2017-01-23       Impact factor: 44.544

5.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

6.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

7.  Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients.

Authors:  Axel Bex; Eric Jonasch; Arjan W Griffioen; Laurie A Mans; Annemarie M A de Graaf; Patrycja Nowak-Sliwinska; Céline L M M de Hoog; Trees A M de Jong; Florry A Vyth-Dreese; Judy R van Beijnum
Journal:  Clin Cancer Res       Date:  2012-05-09       Impact factor: 12.531

8.  Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.

Authors:  Liang Zhang; Manoj Bhasin; Rachel Schor-Bardach; Xiaoen Wang; Michael P Collins; David Panka; Prabhakar Putheti; Sabina Signoretti; David C Alsop; Towia Libermann; Michael B Atkins; James W Mier; S Nahum Goldberg; Rupal S Bhatt
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

Review 9.  Sunitinib re-challenge in advanced renal-cell carcinoma.

Authors:  C Porta; C Paglino; V Grünwald
Journal:  Br J Cancer       Date:  2014-05-06       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.